136 related articles for article (PubMed ID: 9068930)
1. Combination of pravastatin and cyclosporin in transplant patients.
Christians U
Clin Pharmacokinet; 1997 Feb; 32(2):173-4. PubMed ID: 9068930
[No Abstract] [Full Text] [Related]
2. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A.
Park JW; Siekmeier R; Merz M; Krell B; Harder S; März W; Seidel D; Schüler S; Gross W
Int J Clin Pharmacol Ther; 2002 Oct; 40(10):439-50. PubMed ID: 12395976
[TBL] [Abstract][Full Text] [Related]
3. Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine.
Kliem V; Wanner C; Eisenhauer T; Olbricht CJ; Doll R; Boddaert M; O'Grady P; Krekler M; Mangold B; Christians U
Transplant Proc; 1996 Dec; 28(6):3126-8. PubMed ID: 8962211
[No Abstract] [Full Text] [Related]
4. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro.
Katznelson S; Wang XM; Chia D; Ozawa M; Zhong HP; Hirata M; Terasaki PI; Kobashigawa JA
J Heart Lung Transplant; 1998 Apr; 17(4):335-40. PubMed ID: 9588577
[TBL] [Abstract][Full Text] [Related]
5. Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients.
Capone D; Stanziale P; Gentile A; Imperatore P; Pellegrino T; Basile V
Am J Nephrol; 1999; 19(3):411-5. PubMed ID: 10393380
[TBL] [Abstract][Full Text] [Related]
6. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses.
Olbricht C; Wanner C; Eisenhauer T; Kliem V; Doll R; Boddaert M; O'Grady P; Krekler M; Mangold B; Christians U
Clin Pharmacol Ther; 1997 Sep; 62(3):311-21. PubMed ID: 9333107
[TBL] [Abstract][Full Text] [Related]
7. Drugs in cardiac transplantation.
Ballantyne CM
N Engl J Med; 1996 Feb; 334(6):400-1; author reply 401-2. PubMed ID: 8538719
[No Abstract] [Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A.
Park JW; Siekmeier R; Lattke P; Merz M; Mix C; Schüler S; Jaross W
J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):351-61. PubMed ID: 11907637
[TBL] [Abstract][Full Text] [Related]
9. [Utility of pravastin in cardiac transplant dyslipidemia].
Martínez-Dolz L; Almenar Bonet L; Arnau Vives MA; Rueda Soriano J; Osa Sáez A; Dicenta Gisbert F; Palencia Pérez M
Rev Clin Esp; 2002 Sep; 202(9):489-91. PubMed ID: 12236939
[TBL] [Abstract][Full Text] [Related]
10. Effects of pravastatin in heart transplant recipients: implications of Kobashigawa et al.
Gotto AM
Curr Opin Lipidol; 1995 Dec; 6(6):341-3. PubMed ID: 8750244
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression.
Hedman M; Neuvonen PJ; Neuvonen M; Holmberg C; Antikainen M
Clin Pharmacol Ther; 2004 Jan; 75(1):101-9. PubMed ID: 14749696
[TBL] [Abstract][Full Text] [Related]
12. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients.
Regazzi MB; Iacona I; Campana C; Raddato V; Lesi C; Perani G; Gavazzi A; Viganò M
Transplant Proc; 1993 Aug; 25(4):2732-4. PubMed ID: 8356729
[No Abstract] [Full Text] [Related]
13. The effect of pravastatin on acute rejection after kidney transplantation--a pilot study.
Katznelson S; Wilkinson AH; Kobashigawa JA; Wang XM; Chia D; Ozawa M; Zhong HP; Hirata M; Cohen AH; Teraski PI
Transplantation; 1996 May; 61(10):1469-74. PubMed ID: 8633373
[TBL] [Abstract][Full Text] [Related]
14. Myopathy associated with HMG-CoA reductase inhibitors (HMGRIs) and cyclosporin A: evaluation in a rat model.
Smith PF; Eydelloth RS; Grossman SJ; Stubbs RJ; Schwartz MS; Germershausen JI; MacDonald JS
Eur Heart J; 1992 Jul; 13 Suppl B():2-6. PubMed ID: 1644096
[No Abstract] [Full Text] [Related]
15. Effects of pravastatin in the elderly.
Iwata H; Aoyama T; Kami M
Ann Intern Med; 2002 Jun; 136(11):W2. PubMed ID: 12044146
[No Abstract] [Full Text] [Related]
16. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
17. [Statins as new therapeutic possibility in osteoporosis?].
Laufs U; Werner N; Böhm M; Nickenig G
Dtsch Med Wochenschr; 2001 May; 126(19):565-8. PubMed ID: 11402915
[No Abstract] [Full Text] [Related]
18. More on PROSPER.
Wierzbicki AS; Mikhailidis DP; Reynolds TM
Lancet; 2003 Mar; 361(9363):1135-6; author reply 1136. PubMed ID: 12672344
[No Abstract] [Full Text] [Related]
19. Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A.
Regazzi MB; Iacona I; Campana C; Gavazzi A; Viganò M; Perani G
Transplant Proc; 1994 Oct; 26(5):2644-5. PubMed ID: 7940825
[No Abstract] [Full Text] [Related]
20. Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions.
Derks M; Abt M; Phelan M; Turnbull L; Meneses-Lorente G; Bech N; White AM; Parr G
J Clin Pharmacol; 2010 Oct; 50(10):1188-201. PubMed ID: 20489031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
